Novavax Inc vs Toyota Motor Corp — how do they compare? Novavax Inc trades at $7.95 (market cap $1.30B), while Toyota Motor Corp trades at $189.04 (market cap $223.57B). The key difference: Toyota Motor Corp is far larger — about 172× Novavax Inc's market cap, and Toyota Motor Corp pays a 3.32% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TM | |
|---|---|---|
Market Cap | $1.30B | $223.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $248.29 |
52-Week Low | $6.22 | $166.50 |
Enterprise Value | $879.40M | $417.39B |
Dividend Yield | — | 3.32% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Toyota Motor (TM) trades at $190.09, up 1.39% with bullish technical signals and strong fundamentals. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $7.57 exceeding expectations by 62%. Valuation remains attractive with P/E of 8.48 and P/B of 0.95, while revenue growth continues at $48.04T for 2025. Technical indicators show bullish moving averages and support at $189.
Outlook remains positive given strong hybrid vehicle demand and raised earnings guidance, though risks include China sales weakness and recall-related costs. Analyst consensus leans cautious with 62.5% hold ratings despite no sell recommendations. The stock presents value opportunity with solid cash flow generation and market leadership position.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →